MSI1 and neoplasm: These lead compounds proved suitable in cellulo and in vivo to impair oncoRBP function, as demonstrated here by the inhibition of MSI1-enhanced CD44 expression and induction of tumor cell differentiation by the MSI1 inhibitor luteolin.